Coya Therapeutics (COYA) Payables (2021 - 2026)
Coya Therapeutics (COYA) reported Payables of $948192.0 for Q1 2026, down 43.89% on a YoY basis from $1.7 million in Q1 2025, and down 10.64% sequentially from $1.1 million in Q4 2025.
Coya Therapeutics (COYA) Payables (2021 - 2026) Analysis & Trends
Coya Therapeutics (COYA) has 6 years of Payables data on file, last reported at $948192.0 in Q1 2026.
- For the quarter ending Q1 2026, Payables fell 43.89% year-over-year to $948192.0; the trailing twelve-month figure through Mar 2026 stood at $948192.0 (down 43.89% YoY), and the FY2025 full-year result was $1.1 million, down 33.18% from the prior year.
- Payables retreated to $948192.0 in Q1 2026, from $1.1 million in the prior quarter.
- In the past five years, Payables ranged from a high of $1.9 million in Q2 2024 to a low of $237579.0 in Q2 2023.
- A 5-year average of $1.1 million and a median of $1.1 million in 2025 frame the typical range for Payables.
- Across the five-year window, Payables surged 692.61% in 2024 and plunged 50.54% in 2025, its largest moves.
- Tracing COYA's Payables over 5 years: stood at $1.8 million in 2022, then plunged by 36.34% to $1.2 million in 2023, then surged by 37.42% to $1.6 million in 2024, then slumped by 33.18% to $1.1 million in 2025, then slipped by 10.64% to $948192.0 in 2026.
- Business Quant data shows COYA's Payables at $948192.0 in Q1 2026, $1.1 million in Q4 2025, and $1.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - | 5.74 Mn |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | 10.62 Mn |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | 8.69 Mn |
| 4 | BeOne Medicines | 472.75 Bn | 467.96 Bn | 1.35 Bn | 423.55 Mn |
| 5 | Vertex Pharmaceuticals | 122.14 Bn | 114.89 Bn | 2.59 Bn | 489.30 Mn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | 1.03 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn | 1.52 Bn |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Coya Therapeutics | 97.71 Mn | 46.99 Mn | - | 948,192.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 948,192.00 |
| Dec 31, 2025 | 1.06 Mn |
| Sep 30, 2025 | 1.11 Mn |
| Jun 30, 2025 | 931,344.00 |
| Mar 31, 2025 | 1.69 Mn |
| Dec 31, 2024 | 1.59 Mn |
| Sep 30, 2024 | 336,722.00 |
| Jun 30, 2024 | 1.88 Mn |
| Mar 31, 2024 | 1.59 Mn |
| Dec 31, 2023 | 1.16 Mn |
| Sep 30, 2023 | 633,951.00 |
| Jun 30, 2023 | 237,579.00 |
| Mar 31, 2023 | 541,752.00 |
| Dec 31, 2022 | 1.82 Mn |
| Dec 31, 2021 | 857,567.00 |